PN 101 RS
Alternative Names: PN-101-RSLatest Information Update: 13 Jul 2023
Price :
$50 *
At a glance
- Originator PAEAN Biotechnology
- Class Antihypertensives; Hepatoprotectants
- Mechanism of Action Mitochondria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Adult respiratory distress syndrome; Hearing loss; Non-alcoholic steatohepatitis; Preeclampsia
Most Recent Events
- 13 Jul 2023 Preclinical trials in Hearing loss in South Korea (Parenteral), prior to July 2023 (PAEAN Biotechnology pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in Preeclampsia in South Korea (Parenteral), prior to July 2023 (PAEAN Biotechnology pipeline, July 2023)
- 21 Feb 2023 Preclinical trials in Adult respiratory distress syndrome in South Korea (Parenteral)(PAEAN Biotechnology pipeline, February 2023)